secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-054950
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing
-------------------------------------------------------------------------

- Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.
- Net loss $14.8M for Q1 2024, improved from $17.5M in Q1 2023; R&D expenses $14.1M vs $15.9M.
- Enrollment ongoing in Phase 1 trials for JANX007 (PSMA-TRACTr in mCRPC) and JANX008 (EGFR-TRACTr in solid tumors).
- JANX007 data update and expansion cohort doses anticipated in 2H 2024; JANX008 data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024054950/0000950170-24-054950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024054950/janx-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer